ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

• Status: Active, not recruiting
• Trial end date: 2021-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this pivotal trial is to assess the efficacy, safety and tolerability of CyclASol in comparison to the vehicle for the treatment of signs and symptoms of Dry Eye Disease (DED).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novaliq GmbH
• Treatments: Ophthalmic Solutions

Criteria

Inclusion Criteria:

• Signed ICF (Informed Consent Form)

• Patient-reported history of DED in both eyes

• Current use of OTC (over-the-counter) and/or artificial tears for dry eye symptoms

• Ability and willingness to follow instructions, including participation in all study assessments and visits

Exclusion Criteria:

• Women who are pregnant, nursing or planning a pregnancy

• Unwillingness to submit a urine pregnancy test at screening and the last visit (or early termination visit) if of childbearing potential, or unwillingness to use acceptable means of birth control

• Clinically significant slit-lamp findings or abnormal lid anatomy at screening

• Ocular/periocular malignancy

• History of herpetic keratitis

• Active ocular allergies or ocular allergies that may become active during the study period

• Ongoing ocular or systemic infection at screening or baseline

• Wear of contact lenses within 3 months prior to screening or anticipated use of contact lenses during the study

• Use of topical Cyclosporine A or Liftigrast within 2 months prior to screening

• Intraocular surgery or ocular laser surgery within the previous 6 months, or have any planned ocular and/or lid surgeries over the study period

• Presence of uncontrolled systemic diseases

• Presence of known allergy and/or sensitivity to the study drug or its components

• Randomized in a previous CyclASol trial